76 related articles for article (PubMed ID: 9764910)
1. HIV peptide conjugated to heat-killed bacteria promotes antiviral responses in immunodeficient mice.
Scott DE; Golding H; Huang LY; Inman J; Golding B
AIDS Res Hum Retroviruses; 1998 Sep; 14(14):1263-9. PubMed ID: 9764910
[TBL] [Abstract][Full Text] [Related]
2. Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.
Golding B; Inman J; Highet P; Blackburn R; Manischewitz J; Blyveis N; Angus RD; Golding H
J Virol; 1995 Jun; 69(6):3299-307. PubMed ID: 7745677
[TBL] [Abstract][Full Text] [Related]
3. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
Lapham C; Golding B; Inman J; Blackburn R; Manischewitz J; Highet P; Golding H
J Virol; 1996 May; 70(5):3084-92. PubMed ID: 8627787
[TBL] [Abstract][Full Text] [Related]
4. Mucosal immunity in mice immunized with HIV-1 peptide conjugated to Brucella abortus.
Golding B; Eller N; Levy L; Beining P; Inman J; Matthews N; Scott DE; Golding H
Vaccine; 2002 Jan; 20(9-10):1445-50. PubMed ID: 11818165
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers.
Rubinstein A; Goldstein H; Pettoello-Mantovani M; Mizrachi Y; Bloom BR; Furer E; Althaus B; Que JU; Hasler T; Cryz SJ
AIDS; 1995 Mar; 9(3):243-51. PubMed ID: 7755912
[TBL] [Abstract][Full Text] [Related]
6. Systemic and mucosal immunity in rhesus macaques immunized with HIV-1 peptide and gp120 conjugated to Brucella abortus.
Eller N; Golding H; Inoue S; Beining P; Inman J; Matthews N; Scott DE; Golding B
J Med Primatol; 2004 Aug; 33(4):167-74. PubMed ID: 15271066
[TBL] [Abstract][Full Text] [Related]
7. Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals.
Kozlowski PA; Chen D; Eldridge JH; Jackson S
AIDS Res Hum Retroviruses; 1994 Jul; 10(7):813-22. PubMed ID: 7986587
[TBL] [Abstract][Full Text] [Related]
8. Preliminary results of V3 loop peptide-primary neutralizing domain conjugate phase 1 vaccine trail.
Rubinstein A; Goldstein H; Pettoello-Mantovani M; Cryz SJ
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S149-53. PubMed ID: 7865291
[No Abstract] [Full Text] [Related]
9. Production of a novel antigen by conjugation of HIV-1 to Brucella abortus: studies of immunogenicity, isotype analysis, T-cell dependency, and syncytia inhibition.
Golding B; Golding H; Preston S; Hernandez D; Beining PR; Manischewitz J; Harvath L; Blackburn R; Lizzio E; Hoffman T
AIDS Res Hum Retroviruses; 1991 May; 7(5):435-46. PubMed ID: 1678617
[TBL] [Abstract][Full Text] [Related]
10. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
Staats HF; Nichols WG; Palker TJ
J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
[TBL] [Abstract][Full Text] [Related]
11. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens.
Conley AJ; Conard P; Bondy S; Dolan CA; Hannah J; Leanza WJ; Marburg S; Rivetna M; Rusiecki VK; Sugg EE
Vaccine; 1994 Apr; 12(5):445-51. PubMed ID: 8023553
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
[TBL] [Abstract][Full Text] [Related]
15. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
16. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
[TBL] [Abstract][Full Text] [Related]
17. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
18. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120.
Jankovic D; Caspar P; Zweig M; Garcia-Moll M; Showalter SD; Vogel FR; Sher A
J Immunol; 1997 Sep; 159(5):2409-17. PubMed ID: 9278332
[TBL] [Abstract][Full Text] [Related]
19. A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy.
Gu L; Krendelchtchikova V; Krendelchtchikov A; Oster RA; Fujihashi K; Matthews QL
Virol J; 2014 Jun; 11():112. PubMed ID: 24935650
[TBL] [Abstract][Full Text] [Related]
20. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
Tian H; Xiao Y; Qin L; Chen YH
Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
